Ubs Group Ag 2seventy Bio, Inc. Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in 2seventy Bio, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 23,546 shares of TSVT stock, worth $63,338. This represents 0.0% of its overall portfolio holdings.

Number of Shares

23,546

Previous 15,344 53.45%

Holding current value

$63,338

Previous $59,000 88.14%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$3.85 - $5.05 $31,577 - $41,420	8,202 Added 53.45%	23,546 $111,000
Q2 2024 Aug 13, 2024	SELL	$3.6 - $5.79 $136,872 - $220,135	-38,020 Reduced 71.25%	15,344 $59,000
Q1 2024 May 13, 2024	SELL	$3.09 - $6.0 $54,136 - $105,120	-17,520 Reduced 24.72%	53,364 $285,000
Q4 2023 Feb 09, 2024	BUY	$1.57 - $4.58 $58,807 - $171,553	37,457 Added 112.06%	70,884 $302,000
Q3 2023 Nov 09, 2023	SELL	$3.14 - $11.2 $153,875 - $548,856	-49,005 Reduced 59.45%	33,427 $131,000
Q2 2023 Aug 11, 2023	SELL	$8.45 - $12.48 $915,506 - $1.35 Million	-108,344 Reduced 56.79%	82,432 $834,000
Q1 2023 May 12, 2023	BUY	$9.21 - $14.98 $901,916 - $1.47 Million	97,928 Added 105.47%	190,776 $1.95 Million
Q4 2022 Feb 08, 2023	BUY	$8.57 - $17.0 $642,415 - $1.27 Million	74,961 Added 419.08%	92,848 $869,000
Q3 2022 Nov 10, 2022	BUY	$12.56 - $17.54 $40,694 - $56,829	3,240 Added 22.12%	17,887 $261,000
Q2 2022 Aug 10, 2022	SELL	$10.55 - $18.81 $1.45 Million - $2.59 Million	-137,664 Reduced 90.38%	14,647 $194,000
Q1 2022 May 16, 2022	BUY	$11.67 - $26.72 $1.08 Million - $2.47 Million	92,364 Added 154.08%	152,311 $2.6 Million
Q4 2021 Feb 14, 2022	BUY	$13.77 - $42.56 $825,470 - $2.55 Million	59,947 New	59,947 $1.54 Million

Others Institutions Holding TSVT

# of Institutions

126

Shares Held

45.6M

Call Options Held

122K

Put Options Held

19.8K

View Full List

About 2seventy bio, Inc.

Ticker TSVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,873,600
Market Cap $102M
Description
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a col...

More about TSVT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account